---
authors:
- Ebell, Mark H
category: Research Article
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/40531164/
file_path: 2025/06/abelacimab-has-fewer-bleeds-than-rivaroxaban-but-study-has-s.md
issue: '6'
last_updated: '2025-07-30'
original_format: PubMed
pages: 560-561
patient_population: Adults
peer_reviewed: true
pmid: '40531164'
processed_date: '2025-07-30'
publication_date: '2025-06-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Abelacimab Has Fewer Bleeds Than Rivaroxaban, But Study Has Several Important
  Biases.
topics:
- Family Medicine
volume: '111'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '40531164'
  title: Abelacimab Has Fewer Bleeds Than Rivaroxaban, But Study Has Several Important
    Biases.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '111'
    issue: '6'
  publication_info:
    year: '2025'
    month: '06'
    full_date: '2025-06-01'
  article_ids: {}
  publication_types: *id001
related_articles:
- pmid: '40531164'
  title: Abelacimab Has Fewer Bleeds Than Rivaroxaban, But Study Has Several Important
    Biases.
  authors:
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2025 Jun
- pmid: '40499984'
  title: 'Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis
    From AZALEA-TIMI 71.'
  authors:
  - name: Patel SM
    authtype: Author
    clusterid: ''
  - name: Giugliano RP
    authtype: Author
    clusterid: ''
  - name: Morrow DA
    authtype: Author
    clusterid: ''
  - name: Parkar S
    authtype: Author
    clusterid: ''
  - name: Shapiro H
    authtype: Author
    clusterid: ''
  - name: Hug B
    authtype: Author
    clusterid: ''
  - name: Kuder JF
    authtype: Author
    clusterid: ''
  - name: Goodrich EL
    authtype: Author
    clusterid: ''
  - name: Chen SA
    authtype: Author
    clusterid: ''
  - name: Goodman SG
    authtype: Author
    clusterid: ''
  - name: Joung B
    authtype: Author
    clusterid: ''
  - name: Kiss RG
    authtype: Author
    clusterid: ''
  - name: Wojakowski W
    authtype: Author
    clusterid: ''
  - name: Weitz JI
    authtype: Author
    clusterid: ''
  - name: Murphy SA
    authtype: Author
    clusterid: ''
  - name: Wiviott SD
    authtype: Author
    clusterid: ''
  - name: Bloomfield D
    authtype: Author
    clusterid: ''
  - name: Sabatine MS
    authtype: Author
    clusterid: ''
  - name: Ruff CT
    authtype: Author
    clusterid: ''
  source: J Am Coll Cardiol
  pubdate: 2025 Jun 17
- pmid: '39842011'
  title: Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
  authors:
  - name: Ruff CT
    authtype: Author
    clusterid: ''
  - name: Patel SM
    authtype: Author
    clusterid: ''
  - name: Giugliano RP
    authtype: Author
    clusterid: ''
  - name: Morrow DA
    authtype: Author
    clusterid: ''
  - name: Hug B
    authtype: Author
    clusterid: ''
  - name: Kuder JF
    authtype: Author
    clusterid: ''
  - name: Goodrich EL
    authtype: Author
    clusterid: ''
  - name: Chen SA
    authtype: Author
    clusterid: ''
  - name: Goodman SG
    authtype: Author
    clusterid: ''
  - name: Joung B
    authtype: Author
    clusterid: ''
  - name: Kiss RG
    authtype: Author
    clusterid: ''
  - name: Spinar J
    authtype: Author
    clusterid: ''
  - name: Wojakowski W
    authtype: Author
    clusterid: ''
  - name: Weitz JI
    authtype: Author
    clusterid: ''
  - name: Murphy SA
    authtype: Author
    clusterid: ''
  - name: Wiviott SD
    authtype: Author
    clusterid: ''
  - name: Parkar S
    authtype: Author
    clusterid: ''
  - name: Bloomfield D
    authtype: Author
    clusterid: ''
  - name: Sabatine MS
    authtype: Author
    clusterid: ''
  - name: AZALEA–TIMI 71 Investigators
    authtype: CollectiveName
    clusterid: ''
  source: N Engl J Med
  pubdate: 2025 Jan 23
- pmid: '38429728'
  title: Clot time ratio (CTR) and relation to treatment outcome in patients with
    atrial fibrillation treated with Rivaroxaban.
  authors:
  - name: Onelöv L
    authtype: Author
    clusterid: ''
  - name: Theodorsson E
    authtype: Author
    clusterid: ''
  - name: Božič-Mijovski M
    authtype: Author
    clusterid: ''
  - name: Mavri A
    authtype: Author
    clusterid: ''
  source: Thromb J
  pubdate: 2024 Mar 1
- pmid: '34714969'
  title: Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual
    inhibitor of Factor XI and Factor XIa.
  authors:
  - name: Yi BA
    authtype: Author
    clusterid: ''
  - name: Freedholm D
    authtype: Author
    clusterid: ''
  - name: Widener N
    authtype: Author
    clusterid: ''
  - name: Wang X
    authtype: Author
    clusterid: ''
  - name: Simard E
    authtype: Author
    clusterid: ''
  - name: Cullen C
    authtype: Author
    clusterid: ''
  - name: Al-Saady NM
    authtype: Author
    clusterid: ''
  - name: Lepor NE
    authtype: Author
    clusterid: ''
  - name: Coulter S
    authtype: Author
    clusterid: ''
  - name: Lovern M
    authtype: Author
    clusterid: ''
  - name: Bloomfield D
    authtype: Author
    clusterid: ''
  source: J Thromb Haemost
  pubdate: 2022 Feb
---

# Abelacimab Has Fewer Bleeds Than Rivaroxaban, But Study Has Several Important Biases.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 111, No. 6 | 2025-06-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/40531164/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/40531164/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
